On May 1, 2026, the Fifth Circuit Court of Appeals (the “Fifth Circuit”) issued an opinion in the ongoing litigation regarding the U.S. Food & Drug Administration’s (“FDA”) regulation of mifepristone, a drug approved for use in medically induced abortions and routinely used “off-label” to treat early miscarriages. Ruling in favor of the State... READ MORE
Fifth Circuit Court of Appeals Panel Grants Stay in Case Challenging FDA Regulation of Mifepristone
Posted on May 4, 2026 in Health Law News
Published by: Hall Render
